

SUPPLEMENTAL MATERIALS & METHODS

Construction of *C. jejuni* 81-176 $\Delta 1228$ and $\Delta 1228c$ complemented strain.

The *cjj81176_1228* gene was PCR amplified with iProof (Biorad) from 81-176 genomic DNA using primers 1228-L2 and 1228-R2. A polyA tag was added to the PCR product and it was ligated to a commercially available pGEM-T vector (Promega). The resulting construct pGEMT-1228 was verified by restriction enzyme digestion and sequencing. Inverse PCR was performed on the resulting plasmid with primers 1228-IL1 (*SacI*) and 1228-IR1 (*HincII*) deleting 1014 bp of the gene. The inverse PCR product was digested with *SacI* and *HincII* encoded by the primers and ligated to the similarly digested non-polar kanamycin resistance cassette (*aphA-3*) digested out of pUC18K-2 (1), forming construct pGEMT-*pgp1*Km. The construct was verified by restriction enzyme digestion and naturally transformed into *C. jejuni* 81-176. 81-176 $\Delta 1228$ mutant strains were selected by a Km^R phenotype and verified by PCR and restriction enzyme digestion.

For complementation of 1228, the gene was PCR-amplified from 81-176 genomic DNA and cloned into the pRRC integration vector (2) to form pEF48. The 1228 gene and 330 bp of the upstream sequence containing the putative promoter were PCR amplified with primers 1228-1 (*XbaI*) and 1228-2 (*XbaI*). The PCR product was digested with *XbaI* and ligated to pRRC digested with *XbaI* and dephosphorylated. The resulting construct was verified for orientation by PCR with the 1228 gene in the same orientation as the antibiotic resistance cassette encoded by the vector, and sequenced. Plasmids were inserted into $\Delta 1228$ by natural transformation, and transformants selected on the appropriate antibiotics. Single insertions into the rRNA spacer region were verified by PCR with primers ak233, ak234, ak235 (2) and cat-2 for pRRC.

Confirmation of the $\Delta 1228c$ complemented strain in Mueller-Hinton (MH) and Minimum Essential Medium (MEM) broth: morphology and 1228 expression levels.

Overnight cultures of the 81-176 wild type, $\Delta 1228$ mutant and $\Delta 1228c$ complemented strains were grown in MH biphasic flasks. These were then used to inoculate MH or MEM cultures to an OD₆₀₀ of 0.1. After 4 hours growth, 10 μ l samples were removed, formalin fixed and stained using *Campylobacter jejuni* specific antibodies (Abcam) directly on the glass slides, and imaged at 1000 x. RNA was extracted from the remainder of the sample using a hot-phenol RNA extraction as described elsewhere (3). cDNA was synthesized from each RNA sample using "All-in-one RT Mastermix" (ABM) and qPCR was performed using IQ-SYBR green supermix (Bio-rad). Expression of 1228 was analyzed relative to *C. jejuni* 16sRNA using Bio-rad CFX software

Table S1: Bacterial strains or plasmids used in this study.

Strain or Plasmid	Genotype, serotype or description	Reference or Source
<i>C. jejuni</i>		
81-176	Wild type isolated from a diarrheic patient	(4)
$\Delta pgg1$	81-176 $pgg1::aphA3$; Km ^R	(5)
$\Delta pgg2$	81-176 $\Delta pgg2$	(6)
$\Delta pgg1c$	81-176 $\Delta 1344 rrn::pgg1$ (from pEF35R)	(5)
$\Delta pgg2c$	81-176 $\Delta pgg2 rrn::pgg2$ (from pJV4)	(6)
$\Delta 1228$	81-176 $1228::aphA3$; Km ^R	This study
$\Delta 1228c$	81-176 $\Delta 1228 rrn::1228$ (from pEF48)	This study
<i>E. coli</i>		
DH5 α	F ⁻ , $\phi 80d$ <i>deoR lacZΔM15 endA1 recA1 hsdR17(r_K-m_K+)</i> <i>supE44 thi-1 gyrA96 relA1 Δ(lacZYA-argF) U169</i>	Invitrogen
Plasmids		
pGEM-T	PCR cloning vector; Ap ^R	Promega
pUC18-K2	Source of non-polar <i>aphA3</i> cassette; Ap ^R Km ^R	(1)
pRRC	<i>C. jejuni</i> rRNA spacer integration vector; Cm ^R	(2)
pEF35R	pRRC-1344-1348 coding for 81-76 <i>pgg1</i> and 3816 bp upstream of <i>pgg1</i> cloned in the reverse orientation as the <i>cat</i> cassette; Cm ^R	(5)
pJV4	pRRC containing <i>pgg2</i> cloned with 196 bp of upstream sequence cloned in the same orientation as the <i>cat</i> cassette; Cm ^R	(6)
pGEMT-1228	pGEM-T ligated to <i>1228</i> amplified with 1228-L2 and 1228-R2; Ap ^R	This study
pGEMT-1228-Km	pGEMT-1228 with the <i>1228</i> gene disrupted with the <i>aphA3</i> cassette; Ap ^R Km ^R	This study
pEF48	pRRC containing <i>pgg2</i> cloned with 330 bp of upstream sequence in the same orientation as the <i>cat</i> cassette; Cm ^R	This study

Table S2: Primers used in this study

Primer	Sequence 5' to 3'	Restriction Site	Reference
ak233	GCAAGAGTTTTGCTTATGTTAGCAC		(2)
ak234	GAAATGGGCAGAGTGTATTCTCCG		(2)
ak235	GTGCGGATAATGTTGTTTCTG		(2)
cat-2	GTTTTTTGGATGAATTACAAGA		(5)
1228-L2	TATAACACTTGCTCTAGCGATGATA	<i>XbaI</i>	This study
1228-R2	GTGCTAAAAATTATGAAATAGAT	<i>XbaI</i>	This study
1228-IL1	tggagctccCAAGGTATCTCCATTATCCCAAGTTAGCTC TTCAAC	<i>SacI</i>	This study
1228-IR1	gaagtcgacAATCAACCTAATCCCCAAAAGAA	<i>HincII</i>	This study
1228-1	gctctagaTATAACACTTGCTCTAGCGATGATA	<i>XbaI</i>	This study
1228-2	CAATTAATTGATCTAGATTTTTGTGAAATTAGTG	<i>XbaI</i>	This study
cjj1228F	TTCGTGCTTTTCGAGGAAGT		This study
cjj1228R	ACCCCAAAGTTTACCCATGC		This study
s-Cjej-F	AAGTCGAACGATGAAGCTCC		(7)
s-Cjej-R	CCTACTCAACTTGTGTTAAGC		(7)

REFERENCES

1. **Menard R, Sansonetti PJ, Parsot C.** 1993. Nonpolar mutagenesis of the ipa genes defines IpaB, IpaC, and IpaD as effectors of *Shigella flexneri* entry into epithelial cells. *J Bacteriol* **175**:5899-5906.
2. **Karlyshev AV, Wren BW.** 2005. Development and application of an insertional system for gene delivery and expression in *Campylobacter jejuni*. *Appl Environ Microbiol* **71**:4004-4013.
3. **Stahl M, Friis LM, Nothhaft H, Liu X, Li J, Szymanski CM, Stintzi A.** 2011. L-fucose utilization provides *Campylobacter jejuni* with a competitive advantage. *Proc Natl Acad Sci U S A* **108**:7194-7199.
4. **Korlath JA, Osterholm MT, Judy LA, Forfang JC, Robinson RA.** 1985. A point-source outbreak of campylobacteriosis associated with consumption of raw milk. *J Infect Dis* **152**:592-596.
5. **Firdich E, Biboy J, Adams C, Lee J, Ellermeier J, Giolda LD, Dirita VJ, Girardin SE, Vollmer W, Gaynor EC.** 2012. Peptidoglycan-modifying enzyme Pgp1 is required for helical cell shape and pathogenicity traits in *Campylobacter jejuni*. *PLoS Pathog* **8**:e1002602.
6. **Firdich E, Vermeulen J, Biboy J, Soares F, Taveirne ME, Johnson JG, DiRita VJ, Girardin SE, Vollmer W, Gaynor EC.** 2014. Peptidoglycan LD-carboxypeptidase Pgp2 influences *Campylobacter jejuni* helical cell shape and pathogenic properties and provides the substrate for the DL-carboxypeptidase Pgp1. *J Biol Chem* **289**:8007-8018.
7. **Kurakawa T, Kubota H, Tsuji H, Matsuda K, Asahara T, Takahashi T, Ramamurthy T, Hamabata T, Takahashi E, Miyoshi S, Okamoto K, Mukhopadhyay AK, Takeda Y, Nomoto K.** 2012. Development of a sensitive rRNA-targeted reverse transcription-quantitative polymerase chain reaction for detection of *Vibrio cholerae/mimicus*, *V. parahaemolyticus/alginolyticus* and *Campylobacter jejuni/coli*. *Microbiol Immunol* **56**:10-20.

Supplemental Figure 1. Intracellular survival and IL-8 stimulation by *C. jejuni* cell shape mutants $\Delta pgp1$ and $\Delta pgp2$

(A) Invasion and intracellular survival of the *C. jejuni* $\Delta pgp1$ and $\Delta pgp2$ in the INT407 epithelial cell line was assessed by the gentamicin (Gm) protection assay, as carried out previously (5, 6). The $\Delta pgp1$ and $\Delta pgp2$ infection profile resembled that of wild type. Gm was added 3 h post-infection. After 2 h, the Gm was washed off and the cells were incubated with fresh MEM containing 3% FBS and a low dose of Gm. At each time point, CFUs were determined for each well by lysing the cells with water and plating the dilutions onto MH-TV plates. Data represent the mean \pm SEM of three replicates and are representative of three independent experiments. (B) ELISA was used to quantify IL-8 levels secreted by uninfected INT407 epithelial cell lines and cells infected for 8 and 24h with *C. jejuni* wild type 81-176, $\Delta pgp1$ and $\Delta pgp2$ strains. As previously published, infection with the $\Delta pgp1$ mutant increased IL-8 secretion, and the $\Delta pgp2$ mutant triggered IL-8 secretion levels similar to wild type (5, 6). Data represent the mean \pm SEM of three replicates and are representative of three independent experiments. The asterisk (*) indicates a statistically significant difference using the unpaired Student's t-test, with * indicating $p < 0.05$.

Supplemental Figure 2. Loss of $\Delta 1228$ mutant complementation in MEM.

(A) Wild type *C. jejuni* 81-76 maintains a consistent, helical shape in both nutrient-rich MH medium as well as the nutrient-restricted MEM medium (Top panels). The $\Delta 1228$ defect is evident in both media, with a broader spiral, or "C" shape to the cell (Middle panels). The $\Delta 1228c$ complemented strain shows the restored wild type helical shape in MH medium, but not in MEM medium (Bottom panels). Immunofluorescent images were taken under 1000x magnification. (B) Despite phenotypic differences between media, there were no significant differences in *1228* gene transcription between the wild type and complement strains. The experiment was performed in duplicate and analyzed using Bio-rad software.


Supplemental Figure 3. Enhanced Imaging of *C. jejuni* mucus colonization.

Formalin-fixed, paraffin embedded tissue sections of ceca obtained from *Sigirr*^{-/-} mice infected with wild type and mutant strains, 7 days post-infection at 1000 x magnification. Cell nuclei are stained with DAPI (blue), the goblet cells and secreted mucus are stained with antibodies specific to Muc2 (Green), and *C. jejuni* with *C. jejuni* specific antibodies (red). Both the wild type and $\Delta 1228$ mutants are clearly visible within the mucus-filled crypt, whereas the $\Delta pgp1$ and $\Delta pgp2$ mutants remain on the outside of the mucus layer and the intestinal crypts.

SUPPLEMENTAL FIGURES

FIG. S1

A Survival in intestinal epithelial cells



B Intestinal epithelial cell IL-8 secretion




FIG. S2




FIG. S3

